We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I disagree

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:

Statistic

We use tools such as Google Analytics to track web traffic and check the effectiveness of our site.

Necessary

Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h

  • Bioxodes

    Using disruptive science to treat thromboinflammation at its source, starting with a potential breakthrough therapeutic for stroke.

    Read more
  • BIOX-101

    Our lead candidate with unique mechanism of action on neutrophils and coagulation factors (FXIIa & FXIa).

    Read more

About us

Bioxodes

Bioxodes’ innovative pipeline includes a clinical-stage program for the prevention of thrombosis and neuroinflammation in patients with intracerebral hemorrhage (ICH). Bioxodes is also preparing a Phase 2 trial with BIOX-101 in ischemic stroke.

BIOX-101 demonstrates a powerful dual mode of action, targeting thromboinflammation at its source. It inhibits the activation of neutrophils – the human immune system’s first responders - and the release of neutrophil extracellular traps (NETs). It also inhibits Factors XIa and XIIa of the intrinsic coagulation pathway, exerting a powerful antithrombotic effect. Crucially, it does so without increasing bleeding.

In parallel, Bioxodes is developing a pipeline of drug candidates with the objectives to treat chronic thrombo-inflammatory and inflammatory diseases. The goal is to leverage the activity of BIOX-101 against neutrophil activation and NETs formation.

BIOX-101 is our lead asset, topping a pipeline of therapeutic candidates targeting thrombo-inflammatory diseases. We are currently preparing for a Phase 2b clinical trial of BIOX-101 in intracerebral hemorrhage (ICH), a condition with significant unmet medical need. BIOX-101 has received Orphan Drug Designation in both Europe and the U.S. for this indication.

 

video testimonial

Prof Robin Lemmens, a world-renowned stroke expert, is the lead Investigator of the current Phase 2a trial for BIOX-101.

“Stroke is worldwide one of the main causes for mortality,” he says in this video. “We are really in need to find medication hear to try and improve their prognosis.” Professor Lemmens, the head of the stroke unit at the University Hospital Leuven (Belgium), was speaking at an investor event Bioxodes had organized in Zurich, in February 2024.

Product

All products

Advisory Board

All Key Opinion Leaders
  • Robin Lemmens

    Robin Lemmens , M.D.

    Leuven, Belgium

    Read more
  • Rustam Al-Shahi Salman

    Rustam Al-Shahi Salman , MA MB BChir PhD FRCP Edin FHEA FESO

    Edinburgh, United Kingdom

    Read more
  • Matthias Endres

    Matthias Endres , M.D.

    Berlin, Germany

    Read more
  • David Seiffge

    David Seiffge , M.D.

    Bern, Switzerland

    Read more
  • Charlotte Cordonnier

    Charlotte Cordonnier , M.D.

    Lille, France

    Read more
  • Denis Vivien

    Denis Vivien , Ph.D

    Caen, France

    Read more
  • Cedric Hermans

    Cedric Hermans , M.D, Ph.D, FRCP (Lon, Edin)

    Brussels, Belgium

    Read more
  • Ashkan Shoamanesh

    Ashkan Shoamanesh , M.D.

    Hamilton, Canada

    Read more
  • Magdy Selim

    Magdy Selim , M.D., PhD.

    Boston, United-States

    Read more

Recents News

Investors

Invest in us

Why invest

Bioxodes is a Belgian private company, founded in 2013. The Company has received fundings from both the public and private investors.

  • Sfpi - Fpim
  • Financière spin-off Luxembourgeoise
  • Sambrinvest
  • LSRP - Life Sciences Research Partners
  • Business angels
All investors